Latest Insider Transactions at Bicycle Therapeutics PLC (BCYC)
This section provides a real-time view of insider transactions for Bicycle Therapeutics PLC (BCYC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BICYCLE THERAPEUTICS plc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BICYCLE THERAPEUTICS plc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 23
2020
|
Lee Kalowski President and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,189
+50.0%
|
$17,189
$1.56 P/Share
|
|
Jul 15
2020
|
Glaxosmithkline PLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
3,147
-0.08%
|
$59,793
$19.33 P/Share
|
|
Jul 14
2020
|
Glaxosmithkline PLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,597
-0.08%
|
$30,343
$19.27 P/Share
|
|
May 28
2019
|
Tybourne Capital Management (Hk) LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
364,286
+15.69%
|
$5,100,004
$14.0 P/Share
|
|
May 28
2019
|
Tybourne Capital Management (Hk) LTD > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
139,264
+8.04%
|
-
|
|
May 28
2019
|
Tybourne Capital Management (Hk) LTD > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,454,411
+50.0%
|
-
|
|
May 28
2019
|
Glaxosmithkline PLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
385,714
+16.76%
|
$5,399,996
$14.0 P/Share
|
|
May 28
2019
|
Glaxosmithkline PLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,529,561
+39.69%
|
-
|
|
May 28
2019
|
Novartis Bioventures LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
168,630
+8.7%
|
$2,360,820
$14.0 P/Share
|
|
May 28
2019
|
Novartis Bioventures LTD > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,529,561
+39.22%
|
-
|
|
May 28
2019
|
Novartis Bioventures LTD > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
71,450
+6.9%
|
-
|